| Title |
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
|
|---|---|
| Published in |
European Journal of Preventive Cardiology, August 2022
|
| DOI | 10.1093/eurjpc/zwac176 |
| Pubmed ID | |
| Authors |
Kunihiro Matsushita, Stephen Kaptoge, Steven HJ Hageman, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya Surapaneni, Luanluan Sun, Johan Arnlov, Milica Bozic, Hermann Brenner, Nigel J Brunskill, Alex R Chang, Rajkumar Chinnadurai, Massimo Cirillo, Adolfo Correa, Natalie Ebert, Kai-Uwe Eckardt, Ron T Gansevoort, Orlando Gutierrez, Farzad Hadaegh, Jiang He, Shih-Jen Hwang, Tazeen H Jafar, Simerjot K Jassal, Takamasa Kayama, Csaba P Kovesdy, Gijs W Landman, Andrew S Levey, Donald M Lloyd-Jones, Rupert W Major, Katsuyuki Miura, Paul Muntner, Girish N Nadkarni, Christoph Nowak, Takayoshi Ohkubo, Michelle J Pena, Kevan R Polkinghorne, Toshimi Sairenchi, Elke Schaeffner, Markus P Schneider, Varda Shalev, Michael G Shlipak, Marit D Solbu, Nikita Stempniewicz, James Tollitt, José M Valdivielso, Joep van der Leeuw, Angela Yee-Moon Wang, Chi-Pang Wen, Mark Woodward, Kazumasa Yamagishi, Hiroshi Yatsuya, Luxia Zhang, Jannick AN Dorresteijn, Emanuele Di Angelantonio, Frank LJ Visseren, Lisa Pennells, Josef Coresh, Chronic Kidney Disease Prognosis Consortium |
| Abstract |
The 2021 ESC guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, SCORE2 and SCORE2-OP, to predict CVD risk. We developed and validated an "Add-on" to incorporate CKD measures into these algorithms, using a validated approach. In 3,054,840 participants from 34 datasets, we developed three Add-ons (eGFR only, eGFR + urinary albumin-to-creatinine ratio [ACR] [the primary Add-on], and eGFR + dipstick proteinuria) for SCORE2 and SCORE2-OP. We validated c-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,997,719 participants from 34 different datasets. In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved c-statistic by 0.006 (95%CI 0.004-0.008) and 0.016 (0.010-0.023), respectively, for SCORE2 and 0.012 (0.009-0.015) and 0.024 (0.014-0.035), respectively, for SCORE2-OP. Similar results were seen when we included individuals with diabetes and tested the CKD Add-on (eGFR + dipstick). In 57,485 European participants with CKD, SCORE2 or SCORE2-OP with a CKD Add-on showed a significant NRI (e.g., 0.100 [0.062-0.138] for SCORE2) compared to the qualitative approach in the ESC guideline. Our Add-ons with CKD measures improved CVD risk prediction beyond SCORE2 and SCORE2-OP. This approach will help clinicians and patients with CKD refine risk prediction and further personalize preventive therapies for CVD. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 11% |
| Student > Ph. D. Student | 5 | 7% |
| Student > Bachelor | 2 | 3% |
| Student > Master | 2 | 3% |
| Professor > Associate Professor | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 48 | 68% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 17% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Unspecified | 1 | 1% |
| Mathematics | 1 | 1% |
| Nursing and Health Professions | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 50 | 70% |